Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 2870Carcinoma, Non-Small-Cell Lung 2420Breast Neoplasms 2065Colorectal Neoplasms 1239Neoplasm Metastasis 1223Prostatic Neoplasms 1076Melanoma 972Multiple Myeloma 960Ovarian Neoplasms 899Recurrence 849Leukemia, Myeloid, Acute 807Lung Neoplasms 756Pancreatic Neoplasms 750Lymphoma, Non-Hodgkin 726Lymphoma 660Stomach Neoplasms 622Carcinoma, Hepatocellular 564Carcinoma, Renal Cell 544Squamous Cell Carcinoma of Head and Neck 525Leukemia, Lymphocytic, Chronic, B-Cell 493Lymphoma, Follicular 468Head and Neck Neoplasms 449Glioblastoma 435Advanced Solid Tumors 430Small Cell Lung Carcinoma 408Triple Negative Breast Neoplasms 407Lymphoma, Large B-Cell, Diffuse 398Leukemia 394Uterine Cervical Neoplasms 367Advanced Solid Tumor 349

Interventions

Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Neuroendocrine Neoplasms × Clear all
NCT06132113 2026-05-27

DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Boehringer Ingelheim

Phase 1 Recruiting
55 enrolled
Endocrine

Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡